BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Terashima K, Demizu Y, Hashimoto N, Jin D, Mima M, Fujii O, Niwa Y, Takatori K, Kitajima N, Sirakawa S. A phase I/II study of gemcitabine-concurrent proton radiotherapy for locally advanced pancreatic cancer without distant metastasis. Radiother Oncol. 2012;103:25-31. [PMID: 22300608 DOI: 10.1016/j.radonc.2011.12.029] [Cited by in Crossref: 72] [Cited by in F6Publishing: 54] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Hiroshima Y, Fukumitsu N, Saito T, Numajiri H, Murofushi KN, Ohnishi K, Nonaka T, Ishikawa H, Okumura T, Sakurai H. Concurrent chemoradiotherapy using proton beams for unresectable locally advanced pancreatic cancer. Radiother Oncol 2019;136:37-43. [PMID: 31015127 DOI: 10.1016/j.radonc.2019.03.012] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
2 Nichols RC, Huh S, Li Z, Rutenberg M. Proton therapy for pancreatic cancer. World J Gastrointest Oncol 2015;7:141-7. [PMID: 26380057 DOI: 10.4251/wjgo.v7.i9.141] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
3 Lee D, Komatsu S, Terashima K, Toyama H, Matsuo Y, Takahashi D, Suga M, Nishimura N, Tai K, Kido M, Demizu Y, Tokumaru S, Okimoto T, Sasaki R, Fukumoto T. Surgical spacer placement for proton radiotherapy in locally advanced pancreatic body and tail cancers: initial clinical results. Radiat Oncol 2021;16:3. [PMID: 33407648 DOI: 10.1186/s13014-020-01731-z] [Reference Citation Analysis]
4 Mizuhata M, Takamatsu S, Shibata S, Bou S, Sato Y, Kawamura M, Asahi S, Tameshige Y, Maeda Y, Sasaki M, Kumano T, Kobayashi S, Yamamoto K, Tamamura H, Gabata T. Respiratory-gated Proton Beam Therapy for Hepatocellular Carcinoma Adjacent to the Gastrointestinal Tract without Fiducial Markers. Cancers (Basel) 2018;10:E58. [PMID: 29466294 DOI: 10.3390/cancers10020058] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
5 Rutenberg MS, Nichols RC. Proton beam radiotherapy for pancreas cancer. J Gastrointest Oncol 2020;11:166-75. [PMID: 32175120 DOI: 10.21037/jgo.2019.03.02] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
6 Kawashiro S, Yamada S, Okamoto M, Ohno T, Nakano T, Shinoto M, Shioyama Y, Nemoto K, Isozaki Y, Tsuji H, Kamada T. Multi-institutional Study of Carbon-ion Radiotherapy for Locally Advanced Pancreatic Cancer: Japan Carbon-ion Radiation Oncology Study Group (J-CROS) Study 1403 Pancreas. Int J Radiat Oncol Biol Phys 2018;101:1212-21. [PMID: 29907490 DOI: 10.1016/j.ijrobp.2018.04.057] [Cited by in Crossref: 47] [Cited by in F6Publishing: 28] [Article Influence: 15.7] [Reference Citation Analysis]
7 Dell'Oro M, Short M, Wilson P, Bezak E. Clinical Limitations of Photon, Proton and Carbon Ion Therapy for Pancreatic Cancer. Cancers (Basel) 2020;12:E163. [PMID: 31936565 DOI: 10.3390/cancers12010163] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
8 Hirata T, Teshima T, Nishiyama K, Ogawa K, Otani K, Kawaguchi Y, Konishi K, Tomita Y, Takahashi H, Ohigashi H, Ishikawa O. Histopathological effects of preoperative chemoradiotherapy for pancreatic cancer: an analysis for the impact of radiation and gemcitabine doses. Radiother Oncol 2015;114:122-7. [PMID: 25614389 DOI: 10.1016/j.radonc.2015.01.004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
9 Kim TH, Lee WJ, Woo SM, Kim H, Oh ES, Lee JH, Han SS, Park SJ, Suh YG, Moon SH, Kim SS, Kim DY. Effectiveness and Safety of Simultaneous Integrated Boost-Proton Beam Therapy for Localized Pancreatic Cancer. Technol Cancer Res Treat 2018;17:1533033818783879. [PMID: 29962281 DOI: 10.1177/1533033818783879] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
10 Ng SP, Koay EJ. Current and emerging radiotherapy strategies for pancreatic adenocarcinoma: stereotactic, intensity modulated and particle radiotherapy. Ann Pancreat Cancer 2018;1:22. [PMID: 30198024 DOI: 10.21037/apc.2018.07.03] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
11 Shinoto M, Yamada S, Terashima K, Yasuda S, Shioyama Y, Honda H, Kamada T, Tsujii H, Saisho H; Working Group for Pancreas Cancer. Carbon Ion Radiation Therapy With Concurrent Gemcitabine for Patients With Locally Advanced Pancreatic Cancer. Int J Radiat Oncol Biol Phys. 2016;95:498-504. [PMID: 26883565 DOI: 10.1016/j.ijrobp.2015.12.362] [Cited by in Crossref: 64] [Cited by in F6Publishing: 51] [Article Influence: 10.7] [Reference Citation Analysis]
12 Badiyan SN, Hallemeier CL, Lin SH, Hall MD, Chuong MD. Proton beam therapy for gastrointestinal cancers: past, present, and future. J Gastrointest Oncol 2018;9:962-71. [PMID: 30505599 DOI: 10.21037/jgo.2017.11.07] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
13 Konski A, Meyer JE, Joiner M, Hall MJ, Philip P, Shields A, McSpadden E, Choi M, Adaire B, Duncan G, Meropol NJ, Cescon TP, Cohen SJ. Multi-institutional phase I study of low-dose ultra-fractionated radiotherapy as a chemosensitizer for gemcitabine and erlotinib in patients with locally advanced or limited metastatic pancreatic cancer. Radiother Oncol 2014;113:35-40. [PMID: 25441058 DOI: 10.1016/j.radonc.2014.08.014] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
14 Durante M, Tommasino F, Yamada S. Modeling Combined Chemotherapy and Particle Therapy for Locally Advanced Pancreatic Cancer. Front Oncol 2015;5:145. [PMID: 26217585 DOI: 10.3389/fonc.2015.00145] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
15 Sakurai H, Ishikawa H, Okumura T. Proton beam therapy in Japan: current and future status. Jpn J Clin Oncol 2016;46:885-92. [PMID: 27534798 DOI: 10.1093/jjco/hyw102] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 4.6] [Reference Citation Analysis]
16 Combs SE. Individualized radiotherapy (iRT) concepts for locally advanced pancreatic cancer (LAPC): indications and prognostic factors. Langenbecks Arch Surg 2015;400:749-56. [DOI: 10.1007/s00423-015-1309-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
17 Barcellini A, Peloso A, Pugliese L, Vitolo V, Cobianchi L. Locally Advanced Pancreatic Ductal Adenocarcinoma: Challenges and Progress. Onco Targets Ther 2020;13:12705-20. [PMID: 33335406 DOI: 10.2147/OTT.S220971] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Kim KS, Wu HG. Who Will Benefit from Charged-Particle Therapy? Cancer Res Treat 2021;53:621-34. [PMID: 34176253 DOI: 10.4143/crt.2021.299] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Renaud J, Palmans H, Sarfehnia A, Seuntjens J. Absorbed dose calorimetry. Phys Med Biol 2020;65:05TR02. [DOI: 10.1088/1361-6560/ab4f29] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
20 Fujinaga H, Sakai Y, Yamashita T, Arai K, Terashima T, Komura T, Seki A, Kawaguchi K, Nasti A, Yoshida K, Wada T, Yamamoto K, Kume K, Hasegawa T, Takata T, Honda M, Kaneko S. Biological characteristics of gene expression features in pancreatic cancer cells induced by proton and X-ray irradiation. Int J Radiat Biol. 2019;95:571-579. [PMID: 30557072 DOI: 10.1080/09553002.2019.1558297] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
21 Koay EJ, Hanania AN, Hall WA, Taniguchi CM, Rebueno N, Myrehaug S, Aitken KL, Dawson LA, Crane CH, Herman JM, Erickson B. Dose-Escalated Radiation Therapy for Pancreatic Cancer: A Simultaneous Integrated Boost Approach. Pract Radiat Oncol 2020;10:e495-507. [PMID: 32061993 DOI: 10.1016/j.prro.2020.01.012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
22 Verma V, Lin SH, Simone CB 2nd, Mehta MP. Clinical outcomes and toxicities of proton radiotherapy for gastrointestinal neoplasms: a systematic review. J Gastrointest Oncol 2016;7:644-64. [PMID: 27563457 DOI: 10.21037/jgo.2016.05.06] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 6.8] [Reference Citation Analysis]
23 Dolde K, Naumann P, Dávid C, Gnirs R, Kachelrieß M, Lomax AJ, Saito N, Weber DC, Pfaffenberger A, Zhang Y. 4D dose calculation for pencil beam scanning proton therapy of pancreatic cancer using repeated 4DMRI datasets. Phys Med Biol 2018;63:165005. [PMID: 30020079 DOI: 10.1088/1361-6560/aad43f] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
24 Abi Jaoude J, Kouzy R, Nguyen ND, Lin D, Noticewala SS, Ludmir EB, Taniguchi CM. Radiation therapy for patients with locally advanced pancreatic cancer: Evolving techniques and treatment strategies. Curr Probl Cancer 2020;44:100607. [PMID: 32471736 DOI: 10.1016/j.currproblcancer.2020.100607] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
25 Akasaka H, Mizushina Y, Yoshida K, Ejima Y, Mukumoto N, Wang T, Inubushi S, Nakayama M, Wakahara Y, Sasaki R. MGDG extracted from spinach enhances the cytotoxicity of radiation in pancreatic cancer cells. Radiat Oncol 2016;11:153. [PMID: 27876069 DOI: 10.1186/s13014-016-0729-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
26 Dolde K, Naumann P, Dávid C, Kachelriess M, Lomax AJ, Weber DC, Saito N, Burigo LN, Pfaffenberger A, Zhang Y. Comparing the effectiveness and efficiency of various gating approaches for PBS proton therapy of pancreatic cancer using 4D-MRI datasets. Phys Med Biol 2019;64:085011. [PMID: 30893660 DOI: 10.1088/1361-6560/ab1175] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
27 Hirai T, Saito S, Fujimori H, Matsushita K, Nishio T, Okayasu R, Masutani M. Radiosensitization by PARP inhibition to proton beam irradiation in cancer cells. Biochem Biophys Res Commun 2016;478:234-40. [PMID: 27425251 DOI: 10.1016/j.bbrc.2016.07.062] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 4.6] [Reference Citation Analysis]
28 Corkum MT, Liu W, Palma DA, Bauman GS, Dinniwell RE, Warner A, Mishra MV, Louie AV. Online advertising and marketing claims by providers of proton beam therapy: are they guideline-based? Radiat Oncol 2018;13:43. [PMID: 29544511 DOI: 10.1186/s13014-018-0988-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
29 Ng SP, Herman JM. Stereotactic Radiotherapy and Particle Therapy for Pancreatic Cancer. Cancers (Basel) 2018;10:E75. [PMID: 29547526 DOI: 10.3390/cancers10030075] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
30 Liermann J, Shinoto M, Syed M, Debus J, Herfarth K, Naumann P. Carbon ion radiotherapy in pancreatic cancer: A review of clinical data. Radiother Oncol 2020;147:145-50. [PMID: 32416281 DOI: 10.1016/j.radonc.2020.05.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]
31 Gupta P, Totti S, Pérez-mancera PA, Dyke E, Nisbet A, Schettino G, Webb R, Velliou EG. Chemoradiotherapy screening in a novel biomimetic polymer based pancreatic cancer model. RSC Adv 2019;9:41649-63. [DOI: 10.1039/c9ra09123h] [Cited by in Crossref: 6] [Article Influence: 3.0] [Reference Citation Analysis]
32 Sota Y, Einama T, Kobayashibayashi K, Fujinuma I, Tsunenari T, Takihata Y, Iwasaki T, Miyata Y, Okamoto K, Kajiwara Y, Shinto E, Tsujimoto H, Yasuda S, Isozaki Y, Yamada S, Yamamoto J, Ueno H, Kishi Y. Recurrent cholangiocarcinoma with long-term survival by multimodal treatment: A case report. Mol Clin Oncol 2021;14:72. [PMID: 33732458 DOI: 10.3892/mco.2021.2234] [Reference Citation Analysis]
33 Mizumoto T, Terashima K, Matsuo Y, Nagano F, Demizu Y, Mima M, Sulaiman NS, Tokumaru S, Okimoto T, Toyama H, Fukumoto T. Proton Radiotherapy for Isolated Local Recurrence of Primary Resected Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol 2019;26:2587-94. [PMID: 31147994 DOI: 10.1245/s10434-019-07471-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
34 Shinoto M, Ebner DK, Yamada S. Particle Radiation Therapy for Gastrointestinal Cancers. Curr Oncol Rep 2016;18:17. [PMID: 26849660 DOI: 10.1007/s11912-016-0499-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
35 Ohira S, Wada K, Hirata T, Kanayama N, Ikawa T, Karino T, Nitta Y, Isono M, Ueda Y, Miyazaki M, Koizumi M, Teshima T. Clinical implementation of contrast-enhanced four-dimensional dual-energy computed tomography for target delineation of pancreatic cancer. Radiotherapy and Oncology 2018;129:105-11. [DOI: 10.1016/j.radonc.2018.01.012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
36 Durante M, Paganetti H. Nuclear physics in particle therapy: a review. Rep Prog Phys 2016;79:096702. [DOI: 10.1088/0034-4885/79/9/096702] [Cited by in Crossref: 126] [Cited by in F6Publishing: 61] [Article Influence: 25.2] [Reference Citation Analysis]
37 Dolde K, Zhang Y, Chaudhri N, Dávid C, Kachelrieß M, Lomax AJ, Naumann P, Saito N, Weber DC, Pfaffenberger A. 4DMRI-based investigation on the interplay effect for pencil beam scanning proton therapy of pancreatic cancer patients. Radiat Oncol 2019;14:30. [PMID: 30732657 DOI: 10.1186/s13014-019-1231-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
38 Zhang X, Huang HJ, Feng D, Yang DJ, Wang CM, Cai QP. Is concomitant radiotherapy necessary with gemcitabine-based chemotherapy in pancreatic cancer? World J Gastroenterol 2014;20:17648-55. [PMID: 25516680 DOI: 10.3748/wjg.v20.i46.17648] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
39 Mohan R, Held KD, Story MD, Grosshans D, Capala J. Proceedings of the National Cancer Institute Workshop on Charged Particle Radiobiology. Int J Radiat Oncol Biol Phys 2018;100:816-31. [PMID: 29485053 DOI: 10.1016/j.ijrobp.2017.12.260] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
40 Dreher C, Habermehl D, Jäkel O, Combs SE. Effective radiotherapeutic treatment intensification in patients with pancreatic cancer: higher doses alone, higher RBE or both? Radiat Oncol 2017;12:203. [PMID: 29282139 DOI: 10.1186/s13014-017-0945-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
41 Loeffler JS, Durante M. Charged particle therapy--optimization, challenges and future directions. Nat Rev Clin Oncol 2013;10:411-24. [PMID: 23689752 DOI: 10.1038/nrclinonc.2013.79] [Cited by in Crossref: 259] [Cited by in F6Publishing: 178] [Article Influence: 32.4] [Reference Citation Analysis]
42 Maemura K, Mataki Y, Kurahara H, Kawasaki Y, Iino S, Sakoda M, Ueno S, Arimura T, Higashi R, Yoshiura T, Shinchi H, Natsugoe S. Comparison of proton beam radiotherapy and hyper-fractionated accelerated chemoradiotherapy for locally advanced pancreatic cancer. Pancreatology 2017;17:833-8. [DOI: 10.1016/j.pan.2017.07.191] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
43 Rosati LM, Kumar R, Herman JM. Integration of Stereotactic Body Radiation Therapy into the Multidisciplinary Management of Pancreatic Cancer. Semin Radiat Oncol 2017;27:256-67. [PMID: 28577833 DOI: 10.1016/j.semradonc.2017.02.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
44 Mima M, Demizu Y, Jin D, Hashimoto N, Takagi M, Terashima K, Fujii O, Niwa Y, Akagi T, Daimon T, Hishikawa Y, Abe M, Murakami M, Sasaki R, Fuwa N. Particle therapy using carbon ions or protons as a definitive therapy for patients with primary sacral chordoma. Br J Radiol 2014;87:20130512. [PMID: 24288399 DOI: 10.1259/bjr.20130512] [Cited by in Crossref: 50] [Cited by in F6Publishing: 35] [Article Influence: 6.3] [Reference Citation Analysis]
45 Fukumitsu N, Okumura T, Hiroshima Y, Ishida T, Numajiri H, Murofushi KN, Ohnishi K, Aihara T, Ishikawa H, Tsuboi K, Sakurai H. Simulation study of dosimetric effect in proton beam therapy using concomitant boost technique for unresectable pancreatic cancers. Jpn J Radiol 2018;36:456-61. [DOI: 10.1007/s11604-018-0743-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
46 Takatori K, Terashima K, Yoshida R, Horai A, Satake S, Ose T, Kitajima N, Kinoshita Y, Demizu Y, Fuwa N. Upper gastrointestinal complications associated with gemcitabine-concurrent proton radiotherapy for inoperable pancreatic cancer. J Gastroenterol. 2014;49:1074-1080. [PMID: 23846547 DOI: 10.1007/s00535-013-0857-3] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
47 Kwak YK, Lee JH, Lee MA, Chun HG, Kim DG, You YK, Hong TH, Jang HS. Definitive concurrent chemoradiotherapy in locally advanced pancreatic cancer. Radiat Oncol J 2014;32:49-56. [PMID: 25061572 DOI: 10.3857/roj.2014.32.2.49] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
48 Bouchart C, Navez J, Closset J, Hendlisz A, Van Gestel D, Moretti L, Van Laethem JL. Novel strategies using modern radiotherapy to improve pancreatic cancer outcomes: toward a new standard? Ther Adv Med Oncol 2020;12:1758835920936093. [PMID: 32684987 DOI: 10.1177/1758835920936093] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
49 Morimoto K, Demizu Y, Hashimoto N, Mima M, Terashima K, Fujii O, Otsuki N, Murakami M, Fuwa N, Nibu K. Particle radiotherapy using protons or carbon ions for unresectable locally advanced head and neck cancers with skull base invasion. Jpn J Clin Oncol 2014;44:428-34. [PMID: 24620027 DOI: 10.1093/jjco/hyu010] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 4.9] [Reference Citation Analysis]
50 Youl M, Hashem S, Brade A, Cummings B, Dawson LA, Gallinger S, Hedley D, Jiang H, Kim J, Krzyzanowska MK, Ringash J, Wong R, Brierley J. Induction gemcitabine plus concurrent gemcitabine and radiotherapy for locally advanced unresectable or resected pancreatic cancer. Clin Oncol (R Coll Radiol) 2014;26:203-9. [PMID: 24462333 DOI: 10.1016/j.clon.2014.01.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
51 Gupta P, Pérez-Mancera PA, Kocher H, Nisbet A, Schettino G, Velliou EG. A Novel Scaffold-Based Hybrid Multicellular Model for Pancreatic Ductal Adenocarcinoma-Toward a Better Mimicry of the in vivo Tumor Microenvironment. Front Bioeng Biotechnol 2020;8:290. [PMID: 32391339 DOI: 10.3389/fbioe.2020.00290] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 12.0] [Reference Citation Analysis]
52 Plastaras JP, Dionisi F, Wo JY. Gastrointestinal cancer: nonliver proton therapy for gastrointestinal cancers. Cancer J 2014;20:378-86. [PMID: 25415682 DOI: 10.1097/PPO.0000000000000085] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
53 Durante M, Orecchia R, Loeffler JS. Charged-particle therapy in cancer: clinical uses and future perspectives. Nat Rev Clin Oncol 2017;14:483-95. [DOI: 10.1038/nrclinonc.2017.30] [Cited by in Crossref: 189] [Cited by in F6Publishing: 122] [Article Influence: 47.3] [Reference Citation Analysis]
54 Nichols RC, George TJ, Zaiden RA, Awad ZT, Asbun HJ, Huh S, Ho MW, Mendenhall NP, Morris CG, Hoppe BS. Proton therapy with concomitant capecitabine for pancreatic and ampullary cancers is associated with a low incidence of gastrointestinal toxicity. Acta Oncologica 2013;52:498-505. [DOI: 10.3109/0284186x.2012.762997] [Cited by in Crossref: 42] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]